Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-26T09:09:40.631Z Has data issue: false hasContentIssue false

16 - Management of cancer of the colon and rectum

Published online by Cambridge University Press:  05 November 2015

By
Loretta Sweeney  and
Richard Adams
Edited by
Louise Hanna ,
Tom Crosby  and
Fergus Macbeth
Loretta Sweeney
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Richard Adams
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Clinical Oncology , pp. 224 - 241
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adam, I. J., Mohamdee, M. O., Martin, I. G., et al. (1994). Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet, 344, 707–711.CrossRefGoogle ScholarPubMed
Adam, R., Delvart, V., Pascal, G., et al. (2004). Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg, 240, 644–657.Google ScholarPubMed
Adams, R., Meade, A., Seymour, M., et al. on behalf of the MRC COIN Trial Investigators. (2011). Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy in the first-line treatment of patients with advanced colorectal cancer: results of the MRC COIN trial. Lancet Oncol., 12, 642–665.CrossRefGoogle ScholarPubMed
Agrawal, J. and Syngal, S. (2005). Colon cancer screening strategies. Curr. Opin. Gastroenterol., 21, 59–63.Google ScholarPubMed
AJCC. (1997). AJCC Cancer Staging Manual, ed. Fleming, I. D., Cooper, J. S., Henson, D. E., et al., 5th edn. Philadelphia: Lippincott-Raven.
Andre, T., Boni, C., Mounedji-Boudiaf, L., et al. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med., 350, 2343–2351.CrossRefGoogle ScholarPubMed
Anonymous, . (2000). Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet, 355, 1588–1596.Google Scholar
Aschele, C., Cionini, L., Lonardi, S., et al. (2011). Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J. Clin. Oncol., 29, 2773–2780.CrossRefGoogle ScholarPubMed
Athreya, S., Moss, J., Urquhart, G., et al. (2006). Colorectal stenting for colonic obstruction: the indications, complications, effectiveness and outcome – 5-year review. Eur. J. Radiol., 60, 91–94.CrossRefGoogle ScholarPubMed
Bingham, S. A., Day, N. E., Luben, R., et al. (2003). Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet, 361, 1496–1501; erratum in Lancet, 362, 1000.CrossRefGoogle ScholarPubMed
Birgisson, H., Pahlman, L., Gunnarsson, U., et al. (2005). Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J. Clin. Oncol., 23, 8697–8705.CrossRefGoogle ScholarPubMed
Bismuth, H., Adam, R., Levi, F., et al. (1996). Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg., 224, 509–520.CrossRefGoogle ScholarPubMed
Burn, J., Bishop, D. T., Mecklin, J. P.,et al. (2008). Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N. Engl. J. Med., 359, 2567–2578.CrossRefGoogle ScholarPubMed
Cammà, C., Giunta, M., Fiorica, F., et al. (2000). Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. J. Am. Med. Assoc., 284, 1008–1015.CrossRefGoogle ScholarPubMed
Casado, E., Pfeiffer, P., Feliu, J., et al. (2008). UFT (tegafur-uracil) in rectal cancer. Ann. Oncol., 19, 1371–1378.CrossRefGoogle Scholar
Ciardiello, F., Lenz, H.J., Kohne, C. H., et al. (2014). Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. Ann. Oncol., 7, 1346–1355.Google Scholar
Chan, A. T., Ogino, S. and Fuchs, C. S. (2009). Aspirin use and survival after diagnosis of colorectal cancer. J. Am. Med. Assoc., 302, 649–658.Google ScholarPubMed
Colorectal Cancer Collaborative Group. (2001). Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet, 358, 1291–1304.
de Gramont, A., Van Cutsem, E., Schmoll, H. J., et al. (2012). Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol., 13, 1225–1233.CrossRefGoogle ScholarPubMed
Douillard, J. Y., Oliner, K. and Siena, S. (2013). Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med., 369, 1023–1034.CrossRefGoogle ScholarPubMed
Dube, S., Heyen, F. and Jenicek, M. (1997). Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis. Colon Rectum, 40, 35–41.CrossRefGoogle ScholarPubMed
Fearon, E. R. and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell, 61, 759–767.CrossRefGoogle ScholarPubMed
Folkesson, J., Birgisson, H., Pahlman, L., et al. (2005). Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J. Clin. Oncol., 23, 5644–5650.CrossRefGoogle ScholarPubMed
Fong, Y. and Salo, J. (1999). Surgical therapy of hepatic colorectal metastasis. Semin. Oncol., 26, 514–523.Google ScholarPubMed
Gérard, J., Azria, D., Gourgou-Bourgade, S., et al. (2010). Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J. Clin. Oncol., 28, 1638–1644.CrossRefGoogle ScholarPubMed
Glynne-Jones, R., Counsell, N., Quirke, P., et al. (2014). Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann. Oncol., 25, 1356–1362.CrossRefGoogle ScholarPubMed
Gray, R. G., Barnwell, J., Hills, R., et al. (2004). QUASAR: a randomised study of adjuvant chemotherapy (CT) vs. observation including 3238 colorectal cancer patients. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol. 22, No. 14S (July 15 Suppl.), 3501.Google Scholar
Haller, D. G., Tabernero, J., Maroun, J., et al. (2011). Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J. Clin. Oncol., 29, 465–471.CrossRefGoogle ScholarPubMed
Hardcastle, J. D., Chamberlain, J. O., Robinson, M. H., et al. (1996). Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet, 348, 1472–1477.CrossRefGoogle ScholarPubMed
Heinemann, V., von Weikersthal, L., Decker, T., et al. (2013). Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J. Clin. Oncol. 31, abstr LBA3506.CrossRefGoogle Scholar
Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 350, 2335–2342.CrossRefGoogle ScholarPubMed
Jacobs, D. R., Jr., Marquart, L., Slavin, J., et al. (1998). Whole-grain intake and cancer: an expanded review and meta-analysis. Nutr. Cancer, 30, 85–96.CrossRefGoogle ScholarPubMed
James, R. D., Donaldson, D., Gray, R., et al. (2003). Randomised clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS). Br. J. Surg., 90, 1200–1212.Google Scholar
Kerr, D. J., Gray, R., McConkey, C., et al. (2000). Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules – less pain, same gain. QUASAR Colorectal Cancer Study Group. Ann. Oncol., 11, 947–955.CrossRefGoogle ScholarPubMed
Key, T. J., Allen, N. E., Spencer, E. A., et al. (2002). The effect of diet on risk of cancer. Lancet, 360, 861–868.CrossRefGoogle ScholarPubMed
Koeberle, D., Betticher, D. C., Von Moos, R., et al. (2013). Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III noninferiority trial (SAKK 41/06). J. Clin. Oncol. 31 (suppl; abstr 3503).Google Scholar
Koopman, M., Antonini, N. F., Douma, J., et al. (2007). Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet, 370, 135–142.CrossRefGoogle ScholarPubMed
Koopman, M., Simkens, L., May, A. M., et al. (2014). Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC). J. Clin. Oncol., 32(5s), 3504.CrossRefGoogle Scholar
Lichtman, S. M. (2004). Chemotherapy in the elderly. Semin. Oncol., 31, 160–174.CrossRefGoogle ScholarPubMed
Loughrey, M., Quirke, P. and Shepherd, N. (2014). Standards and Datasets for Reporting Cancers. Dataset for Colorectal Cancer Histopathology Reports. Version 3. London: The Royal College of Pathologists.Google Scholar
MacFarlane, J. K., Ryall, R. D. and Heald, R. J. (1993). Mesorectal excision for rectal cancer. Lancet, 341, 457–460.CrossRefGoogle ScholarPubMed
Marijnen, C., Peeters, K., Putter, H., et al. (2005). Long term results, toxicity and quality of life in the TME trial. Proc. Am. Soc. Clin. Oncol. Gastrointestinal Cancer Symposium, Abstr. 166.Google Scholar
Martin, R., Joshi, J., Robbins., K., et al. (2011). Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann. Surg. Oncol., 18, 192–198.CrossRefGoogle ScholarPubMed
Maughan, T. (2005). Fluorouracil (FU), oxaliplatin, (OX), CPT-11 (irinotecan, Ir) use and sequencing in advanced colorectal cancer (ACRC): the UK MRC FOCUS (CR08) trial. Proc. Am. Soc. Clin. Oncol. Gastrointestinal Cancers Symposium, Abstr. 165.Google Scholar
Maughan, T., Adams, R. A., Smith, C., et al. on behalf of the MRC COIN Trial Investigators. (2011). The addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for advanced colorectal cancer: results of the MRC COIN trial. Lancet, 18, 2103–2114.Google Scholar
MERCURY Study Group. (2006). Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. Br. Med. J., 333, 779.CrossRef
NHS Executive. (1997). Cancer Guidance Sub-group of the Clinical Outcomes Group. Guidance Improving Outcomes in Colorectal Cancer: The Research Evidence. London: Department of Health.
NICE. (2005). Technology Appraisal 93. Colorectal Cancer (advanced) Irinotecan, Oxaliplatin and Raltitrexed (Review): Guidance. London: NICE.
NICE. (2011). Colorectal Cancer. The Diagnosis and Management of Colorectal Cancer. NICE Clinical Guideline CG 131.London: NICE.
NICE. (2015a). Suspected cancer: recognition and referral. London. National Institute for Health and Care Excellence.
NICE. (2015b). Low-energy contact X-ray brachytherapy (the Papillon technique) for early-stage rectal cancer. NICE interventional procedure guidance 532London: National Institute for Health and Care Excellence.
Nordlinger, B., Sorbye, H., Glimelius, B., et al. (2008). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet, 371, 1007–1016.CrossRefGoogle ScholarPubMed
O'Connell, M. J., Laurie, J. A., Kahn, M., et al. (1998). Prospectively randomised trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J. Clin. Oncol., 16, 295–300.CrossRefGoogle Scholar
Primrose, J., Falk, S., Finch-Jones, M., et al. (2014a). Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol., 15, 601–611.CrossRefGoogle ScholarPubMed
Primrose, J., Perera, R., Gray, A., et al. (2014b). Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer. The FACS randomized clinical trial. J. Am. Med. Assoc., 311, 263–270.CrossRefGoogle ScholarPubMed
Renehan, A. G., Egger, M., Saunders, M. P., et al. (2002). Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. Br. Med. J., 324, 813.CrossRefGoogle ScholarPubMed
Rödel, C., Liersch, T., Becker, H., et al. (2012). Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol., 13, 679–687.CrossRefGoogle ScholarPubMed
Roh, M., Yothers, M., O'Connell, R., et al. (2011). The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J. Clin. Oncol., 29 (suppl; abstr 3503).CrossRefGoogle Scholar
Rowan, A., Halford, S., Gaasenbeek, M., et al. (2005). Refining molecular analysis in the pathways of colorectal carcinogenesis. Clin. Gastro. Hepatol., 3, 1115–1123.CrossRefGoogle ScholarPubMed
Saltz, L. B., Niedzwiecki, D., Hollis, D., et al. (2004). Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol. 22, No. 18S (July 15 Suppl.), 3500.Google Scholar
Saltz, L., Clarke, S., Diaz-Rubio, E., et al. (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol., 20, 2013–2019.Google Scholar
Sargent, D., Marsoni, S., Monges, G., et al. (2010). Defective MMR as a predictive marker for a lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol., 28, 3219–3226.CrossRefGoogle Scholar
Sauer, R., Becker, H., Hohenberger, W., et al. (2004). Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med., 351, 1731–1740.CrossRefGoogle ScholarPubMed
Schmoll, H., Van Cutsem, E., Stein, A., et al. (2012). ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann. Oncol., 23, 2479–2516.CrossRefGoogle ScholarPubMed
Schmoll, H., Haustermans, K., Price, T., et al. (2014). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survival results at interim analysis (abstract). J. Clin. Oncol., 32(5s suppl; abstr. 3501).Google Scholar
Sebag-Montefiore, D., Stephens, R., Steele, R., et al. (2009). Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet, 373, 811–820.CrossRefGoogle ScholarPubMed
Stephens, R., Thompson, L., Quirke, P., et al. (2010). Impact of short-course preoperative radiotherapy for rectal cancer on patients’ quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J. Clin. Oncol., 28, 4233–4239.CrossRefGoogle Scholar
Taieb, J., Tabernero, J., Mini, E., et al. (2014). Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol., 15, 862–873.CrossRefGoogle ScholarPubMed
Taylor, F. G., Quirke, P., Heald, R. J., et al. (2014). Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J. Clin. Oncol., 32, 34–43.CrossRefGoogle ScholarPubMed
Tournigand, C., Cervantes, A., Figer, A., et al. (2006). OPTIMOX1: a randomised study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J. Clin. Oncol., 24, 394–400.CrossRefGoogle Scholar
Treasure, T., Fallowfield, L., Lees, B., et al. (2012). Pulonary metastasectomy in colorectal cancer: the PulMiCC trial. Thorax, 67, 185–187.CrossRefGoogle Scholar
Twelves, C., Wong, A., Nowacki, M. P., et al. (2005). Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med., 352, 2696–2704.CrossRefGoogle ScholarPubMed
Van Cutsem, E., Labianca, R., Bodoky, G., et al. (2009). Randomized phase iii trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage iii colon cancer: PETACC-3. J. Clin. Oncol., 27, 3117–3125.CrossRefGoogle ScholarPubMed
Van Hazel, G., Blackwell, A., Anderson, J., et al. (2004). Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J. Surg. Oncol., 88, 78–85.CrossRefGoogle ScholarPubMed
Vasen, H. F., Watson, P., Mecklin, J. P., et al. (1999). New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology, 116, 1453–1456.CrossRefGoogle Scholar
Wade, T. P., Virgo, K. S., Li, M. J., et al. (1996). Outcomes after detection of metastatic carcinoma of the colon and rectum in a national hospital system. J. Am. Coll. Surg., 182, 353–361.Google Scholar
Willett, C. G. (1999). Technical advances in the treatment of patients with rectal cancer. Int. J. Radiat. Oncol. Biol. Phys, 45, 1107–1108.CrossRefGoogle ScholarPubMed
Wolmark, N., Wieand, H. S., Kuebler, J. P., et al. (2005). A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. J. Clin. Oncol. ASCO Annual Meeting Proceedings, 23 (16 Suppl. I), 3500.Google Scholar
Ychou, M., Raoul, J., Douillard, J., et al. (2005). A phase II randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). J. Clin. Oncol. ASCO Annual Meeting Proceedings, Vol. 23, No. 16S, Part I of II (June 1 Suppl.), 3502.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×